Clopidogrel And Ticagrelor in Healthy Subjects

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

To evaluate the pharmacodynamics of a lower Ticagrelor dose in healthy Korean volunteers compared with standard Clopidogrel agent.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dong-A University
• Treatments: Adenosine; Clopidogrel; Polystyrene sulfonic acid; Ticagrelor; Ticlopidine

Criteria

Inclusion Criteria:

• 12 healthy men

• Aged between 19 and 59 years

• Body mass index (BMI) is between 18.5 and 29.9 kg/m2

• Baseline maximal platelet aggregation (MPA) 10 μmol/L ADP is more than 65%

• To screen for standard results on usual clinical tests

Exclusion Criteria:

• A history of bleeding within 6 months

• Bleeding diathesis

• Hemoglobin < 12g/dl

• History of antiplatelet or anticoagulation treatment within 1 month

• contraindication to the study drug

• Severe hepatic dysfunction (serum liver enzyme or bilirubin >3 times normal limit)

• Patients with hereditary disease such as galactose intolerance, lactase deficiency, glucose-galactose malabsorption

• Previous experience of clinical trials within three months